Novo Nordisk bets on Wegovy capsule to win weight reduction battle past U.S.

Novo Nordisk has instructed CNBC how it’s making ready to go “all in” on launching its Wegovy capsule exterior the U.S, because the battle for dominance of the weight-loss market goes world.

“Once we launch, we’ll go all in,” Novo’s Govt Vice President for Worldwide Operations, Emil Kongshøj Larsen, instructed CNBC in an interview on Tuesday. “It is a main alternative.”

Novo introduced final week that it expects to begin the primary launches exterior of the U.S. later this yr, pending approvals, after the capsule continues to impress with unparalleled U.S. uptake.

The U.S. market accounts for greater than half of the gross sales of each Novo and its chief rival Eli Lilly. However the firms are actually trying more and more to develop the marketplace for weight-loss medication which have revolutionized the pharmaceutical house lately.

Larsen would not title particular nations the place Novo may launch the Wegovy capsule first, saying the drugmaker will “go in line with potential,” highlighting elements similar to affected person curiosity in weight problems remedy, how well-trained docs are, and the existence of potential telehealth companions.

Larsen stated that telehealth had been a technique of broadening entry to sufferers, saying that, in Germany, “it has been sluggish for some time, and hastily, telehealth helps sufferers get entry to remedy in a method that could be very handy and appreciated.”

Whereas Eli Lilly expects gross sales to develop 28% on the midpoint of its steerage this yr, Novo has forecast a drastic decline in gross sales.

Novo hiked its steerage barely final week, however nonetheless expects earnings and gross sales to say no between 4% and 12% in 2026, harm by decrease costs within the U.S. and generic competitors in markets together with India, Canada, Brazil, and China.

That is regardless of Novo gaining an early lead within the oral weight reduction medication with the U.S. launch of the Wegovy capsule in January. Final week, Novo stated whole prescriptions had reached greater than 2 million, as gross sales massively beat expectations in its first quarter regardless of its cheaper price level. 

“We can not have a greater pre-launch in a world that is change into very small on the subject of social media, digital, sentiment, and many others.,” Larsen stated, referring to the uslaunch. “It is also very thrilling for our injectable franchise, as a result of it is energizing the entire Wegovy model,” he added.

Nordea analysts stated in a notice to shoppers that Wegovy is turning into the primary family weight reduction model within the U.S., based mostly on Google Tendencies knowledge, which aligns with prescription tendencies.

In the meantime, Lilly stated on April 30 that greater than 20,000 folks had began taking the rival capsule Foundayo because it launched earlier that month.

Based on analysts intently monitoring weekly U.S. prescription knowledge, Foundayo has recorded far fewer prescriptions in contrast with the Wegovy capsule within the comparable interval, in line with IQVIA knowledge, which does not seize all prescriptions, however provides market watchers a sign of demand. 

Lilly CEO David Ricks instructed CNBC late final month that establishing Foundayo as a model would “take a while.” Foundayo makes use of a special energetic ingredient than Lilly’s blockbuster injectables Mounjaro and Zepbound, whereas Novo’s Wegovy capsule is actually an extension of the corporate’s injectable equivalents. 

“Our ramp goes to be slightly completely different, as a result of it is a new model, a brand new molecule,” Ricks stated. “That is going to play out over quarters, not days… ask folks to take a beat and allow us to execute.”

Barclays analyst Emily Subject famous final week that oral Wegovy and Foundayo are going for various affected person segments, with the previous having “injectable-like efficacy” and the latter maybe being considered as extra of a “starter” GLP-1.

Each Ricks and Novo CEO Mike Doustdar say the capsules are increasing the market, slightly than considerably capitalizing on demand for the injectables.

The capsule format is interesting to many sufferers, and “we imagine [it] will probably be replicated additionally in our a part of the world,” Larsen instructed CNBC, referring to ex-U.S. markets.

Larsen stated Wegovy capsule’s “superior efficacy” meant he wasn’t apprehensive if launched after the competitors in sure markets.

Research have recommended that the capsule leads to extra pronounced weight reduction than Foundayo and has sure cardiovascular advantages, however to this point, no scientific trial has instantly in contrast the 2 medication.

Larsen stated that Novo expects a “very robust uptake” of the Wegovy capsule internationally however not essentially with the identical type of curve as within the U.S.

He stated the U.S. is not a great comparability with different nations as a result of uptake will rely upon the relative worth distinction in comparison with injectable variations.

“We’re not detailing our pricing method to this point, however you may say within the U.S., there is a implausible product, however there’s additionally one other worth level in comparison with injectable remedies.”

He predicted worldwide gross sales might have “an optic curve that is possibly barely extra bent than the U.S. curve.”

Sydbank analyst Soren Hansen instructed CNBC on Wednesday that Wegovy’s launch exterior the U.S. could possibly be “extra selective” and can mirror the corporate’s “potential to satisfy the demand.” He highlighted large European markets such because the U.Ok. and Germany as doubtless early markets for launch, in addition to Novo’s residence nation, Denmark. 

Larsen instructed CNBC that Novo noticed most development for weight problems GLP-1s coming from cash-paying prospects, versus these lined by nationwide healthcare methods or insurers.

“Even in socialized healthcare methods just like the Danish, 99% of all sufferers are paying out of pocket. We would not have imagined that a couple of years again, after we began with weight problems care,” he added.

In late April, Lilly CEO Ricks instructed CNBC that worldwide launches gave the corporate a “large runway.”

“There are a billion folks on the planet who may benefit from these drugs… proper now we’re reaching about 20 million, he stated.

Lilly’s first-quarter income exterior of the U.S. jumped 81% to $7.7 billion, fuelled by a 95% surge in quantity. Income within the U.S. climbed 43% within the quarter to $12.1 billion. “It seems folks wish to shed pounds all all over the world,” Ricks stated.

President Donald Trump’s so-called most-favored-nation drug pricing coverage, whereby costs within the U.S. market are tied to costs in a set of reference nations, has sophisticated drug launches for a lot of pharmaceutical firms.

Novo’s Larsen stated that how European nations handle pricing for medicines would not have an effect on out-of-pocket launches.

“It is, after all, crucial that the European governments additionally settle for that paying for high quality innovation that modifications public well being, as a result of in any other case investments and scientific trials, and many others, will preserve transferring in the direction of the U.S. or China, as we see in the meanwhile,” Larsen stated.